Drug reference

talimogene laherparepvec

oncolytic herpesvirus, cancer vaccine · anticancer, immunomodulator

oncolytic herpesvirus, cancer vaccineanticancer, immunomodulator

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

12 major

SEVERE in our sources

PREGNANCY

—

not curated

Top interactionssee all 12 →

AbataceptSevereDatabaseDDInter
AbemaciclibSevereDatabaseDDInter
AcalabrutinibSevereDatabaseDDInter
AdalimumabSevereDatabaseDDInter

Mechanism

Talimogene laherparepvec (T-VEC) is an oncolytic herpesvirus that replicates within tumors and expresses GM-CSF. Tumor antigens are released after virally induced cell death, and the presence of GM-CSF can promote an antitumor immune response.

Indications

local treatment of unresectable but injectable cutaneous and nodal lesions in patients with melanomainjection of primary or recurrent melanomas including cutaneous and subcutaneous lesions or lymph node deposits that cannot be completely removed by surgery

Side effects

Common

influenza-like symptomsinjection site pain

Drug interactions

Abatacept

Severe

Database

Clinical effect not specified

Source: DDInter

Abemaciclib

Severe

Database

Clinical effect not specified

Source: DDInter

Acalabrutinib

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Adalimumab

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Aflibercept

Severe

Database

Clinical effect not specified

Source: DDInter

Aldesleukin

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Alefacept

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Alemtuzumab

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Altretamine

Severe

Database

Clinical effect not specified

Source: DDInter

Anakinra

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Antithymocyte Immunoglobulin (rabbit)

Severe

Database

Clinical effect not specified

Source: DDInter

Asparaginase Escherichia Coli

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Related guidelines

Cervical cancer screening and management

ICMR · Oncology · 2022

Breast cancer

ESMO · Oncology · 2024

Breast cancer

ICMR · Oncology · 2022

Tobacco-related cancer prevention

ICMR · Oncology · 2021

Primary PCI for acute coronary syndrome

ESC · Cardiology · 2026

Ask House about talimogene laherparepvec

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspace Ask House about this drug

Sources: Goodman & Gilman 14e, Harrison 22e·Verified: 2026-05-10 · House clinical team